GlassScriptPhysician profile
Bayard Won Chang
NPI 1104816255
$3,292.19
in general payments reported to CMS, 2019-2025
27 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $588 · 2021: $612 · 2022: $498 · 2023: $436 · 2024: $435 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $421.23 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $398.96 | 2019-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $389.47 | 2019-2022 | |
| Lilly USA, LLC | $244.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $231.12 | 2020-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $184.97 | 2020-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $181.61 | 2019-2023 | Belsomra |
| Abbvie INC. | $176.60 | 2020-2025 | Ubrelvy |
| Amgen INC. | $146.91 | 2019-2023 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $92.92 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $86.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.68 | 2019-2023 | Xifaxan |
| Lundbeck LLC | $74.80 | 2019-2022 | |
| Amarin Pharma, INC. | $72.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.24 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $65.07 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.23 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.58 | 2023-2024 | Ofev |
| Idorsia Pharmaceuticals US INC | $49.99 | 2023 | Quviviq |
| Boston Scientific Corporation | $43.26 | 2025 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $38.41 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $37.82 | 2021 | |
| Therapeuticsmd, INC. | $34.85 | 2019-2020 | |
| Kaleo, INC. | $21.93 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.50 | 2020 | |
| Sumitomo Pharma America, INC. | $17.10 | 2025 | Gemtesa |
| Allergan, INC. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bayard Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.